The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.
The suit alleges that Natera's Panorama test infringes US Patent No. 9,493,831 patent, which covers sequencing library preparation methods applied to maternal blood samples.
The company is now seeking commercial partners in Brazil to make the Iona test available in the country.
Adam Wolfberg argued that while corporate conflicts are widely discussed, physicians also have financial conflicts that can bias them against new technology.
Poor women have limited access to noninvasive prenatal screening tools, a post at Health Affairs' blog says.
The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.
The Singaporean firm already offers cell-free NIPT testing through its iGene Laboratory and sells a kit to test ovarian cysts for malignancy.
Reuters reports that UK researchers have tested a new approach to screening for Down syndrome and other chromosomal disorders.
The Chinese Academy of Sciences-led team said the approach could lead to a therapeutic strategy for human aneuploidy diseases involving additional chromosomes.
In a study involving almost 23,000 women, DNA reflex testing detect 95 percent of trisomies while avoiding recalls.
In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.
An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.
In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.
In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.